- DocumentSystems Vaccinology of the BNT162b2 MRNA Vaccine in Humansuploaded byChristian Garaffa
- DocumentEffectiveness of MRNA BNT162b2 COVID-19 Vaccine Up to 6 Months in a Large Integrated Health System in the USA a Retrospective Cohort Studyuploaded byChristian Garaffa
- DocumentResistance of SARS CoV 2 Delta Variant to Neutraliuploaded byChristian Garaffa
- DocumentThe BNT162b2 Vaccine Effectiveness Against New COVID-19 Cases and Complications of Breakthrough Casesuploaded byChristian Garaffa
- DocumentReactogenicity Following Two Doses of the BNT162b2 MRNA COVID-19 Vaccineuploaded byChristian Garaffa
- DocumentTime Since SARS-CoV-2 Infection and Humoral Immune Response Following BNT162b2 MRNA Vaccinationuploaded byChristian Garaffa
- DocumentOccurrence of BNT162b2 Vaccine Adverse Reactions is Associated With Enhanced SARS-CoV-2 IgG Antibody Responseuploaded byChristian Garaffa
- DocumentSafety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine Through 6 Monthsuploaded byChristian Garaffa
- DocumentSpike Antibody Waning After Second Dose of BNT162buploaded byChristian Garaffa
- DocumentInfections, Hospitalisations, And Deaths Averted via a Nationwide Vaccination Campaign Using the Pfizer–BioNTech BNT162b2 MRNA COVID-19 Vaccine in Israeluploaded byChristian Garaffa
- DocumentProtection of BNT162b2 Vaccine Booster Against Covid-19 in Israeluploaded byChristian Garaffa
- DocumentDelayed Second Dose of the BNT162b2 Vaccine Innovuploaded byChristian Garaffa
- DocumentAge and Smoking Predict Antibody Titres at 3 Months After the Second Dose of the BNT162b2 COVID-19 Vaccineuploaded byChristian Garaffa
- DocumentNeutralising Antibody Activity Against SARS CoV 2uploaded byChristian Garaffa
- DocumentInitial Observations on Age, Gender, BMI and Hyperuploaded byChristian Garaffa
- DocumentEffect of Previous SARS CoV 2 Infection on Humoraluploaded byChristian Garaffa
- DocumentComparative Immunogenicity of BNT162b2 MRNA Vaccine With Natural SARS-CoV-2 Infectionuploaded byChristian Garaffa
- DocumentBeyond Neutralization for BNT162b2 MRNA Vaccinationuploaded byChristian Garaffa
- DocumentEarly Rate Reductions of SARS CoV 2 Infection anduploaded byChristian Garaffa
- DocumentImmunogenicity and Reactogenicity of BNT162b2 Boosuploaded byChristian Garaffa
- DocumentImmunogenicity of Single Vaccination With BNT162b2uploaded byChristian Garaffa
- DocumentImpact and Effectiveness of MRNA BNT162b2 Vaccine Against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, And Deaths Following a Nationwide Vaccination Campaign in Israeluploaded byChristian Garaffa
- DocumentAssociation Between Previous Infection With SARS Cuploaded byChristian Garaffa
- DocumentA Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 PfizerBioNTech MRNA Vaccineuploaded byChristian Garaffa
- DocumentBNT162b2 Vaccine for Prevention of COVID-19uploaded byChristian Garaffa
- DocumentDecreased Infectivity Following BNT162b2 Vaccinatiuploaded byChristian Garaffa
- DocumentAntibody Response Induced by the Boost Overdose During COVID-19 Heterologous Prime-boost Vaccination Strategyuploaded byChristian Garaffa
- DocumentAntibody Response to First BNT162b2 Dose in Previouploaded byChristian Garaffa
- DocumentBeta SARS CoV 2 Variant and BNT162b2 Vaccine Effecuploaded byChristian Garaffa
- DocumentBNT162b2 COVID 19 Vaccine and Correlates of Humorauploaded byChristian Garaffa
- DocumentDynamics of Antibody Response to BNT162b2 Vaccine After Six Monthsuploaded byChristian Garaffa
- DocumentAntibody Response After Third BNT162b2 Dose in Recipients of Allogeneic HSCTuploaded byChristian Garaffa
- DocumentAntibody Response After Second BNT162b2 Dose in Allogeneic HSCT Recipientsuploaded byChristian Garaffa
- DocumentAssociation Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19uploaded byChristian Garaffa
- DocumentAssociation Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workersuploaded byChristian Garaffa
- DocumentAssociation Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccinationuploaded byChristian Garaffa
- DocumentEffectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2uploaded byChristian Garaffa
- DocumentComparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canadauploaded byChristian Garaffa